Azafaros B.V.

Azafaros B.V. company information, Employees & Contact Information

Explore related pages

Related company profiles:

We are developing new treatment options to help patients with rare metabolic disorders. Azafaros was founded in 2018 by a team of experienced industry professionals and scientists aspiring to address rare genetic metabolic disorders through a pipeline of oral small molecules with disease-modifying potential. Based on discoveries from Leiden University and Amsterdam UMC, Azafaros’s proprietary lead compound, nizubaglustat, will initially address inherited life-threatening lysosomal storage diseases for which there are no effective therapies. This orally available azasugar compound interferes with the metabolism of glycolipids and uniquely affects several key disease pathways through a dual mode of action. Leveraging the know-how of its team and partners in orphan drug development, the company is advancing its lead program in the clinic while further expanding its product pipeline into other rare metabolic diseases through its drug discovery efforts.

Company Details

Employees
24
Founded
-
Address
Gooimeer 2-35, Naarden,1411 Dc,netherlands
Phone
+31 (0) 35 699 30 00
Email
in****@****ros.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
Keywords
Biotech.
HQ
Naarden
Looking for a particular Azafaros B.V. employee's phone or email?

Azafaros B.v. Questions

News

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders - Business Wire

Azafaros Secures € 132M in Oversubscribed Series B Financing to Advance Phase 3 Clinical Programs of Innovative Therapies in Lysosomal Storage Disorders Business Wire

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively - Yahoo Finance

Azafaros Announces Initiation of two Global Phase 3 studies with Nizubaglustat in Niemann-Pick disease Type C (NPC) and GM1/GM2 gangliosidoses, respectively Yahoo Finance

Dutch-based Azafaros raises €132M to develop new treatment options for rare metabolic diseases - Silicon Canals

Dutch-based Azafaros raises €132M to develop new treatment options for rare metabolic diseases Silicon Canals

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing - Business Wire

Azafaros to Present at BIO International Convention 2025 Following Successful €132M Series B Financing Business Wire

Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug - Fierce Biotech

Dutch biotech Azafaros gains €132M series B to fund phase 3 trials of brain-penetrant drug Fierce Biotech

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025 - Business Wire

Azafaros granted important regulatory designations and clearance by European authorities for global Phase 3 studies, to be initiated in 2025 Business Wire

Azafaros BV bags €132m Series B financing - European Biotechnology Magazine

Azafaros BV bags €132m Series B financing European Biotechnology Magazine

Azafaros Raises $150M To Target Rare Neuro-Metabolic Diseases - BioSpace

Azafaros Raises $150M To Target Rare Neuro-Metabolic Diseases BioSpace

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients - Yahoo Finance

Azafaros announces completion of 12-week Phase 2 RAINBOW study evaluating lead asset nizubaglustat in rare disease patients Yahoo Finance

Azafaros Raises €132M in Series B Financing - FinSMEs

Azafaros Raises €132M in Series B Financing FinSMEs

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™ - Yahoo! Finance UK

Azafaros to present data from PRONTO study in patients with GM1 and GM2 gangliosidoses at the 20th annual WORLDSymposium™ Yahoo! Finance UK

European rare disease biotech Azafaros grabs $28M early funding round - Fierce Biotech

European rare disease biotech Azafaros grabs $28M early funding round Fierce Biotech

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA - Business Wire

Azafaros Receives Additional Regulatory Designations for AZ-3102 from FDA, EMA and MHRA Business Wire

Top Azafaros B.V. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant